Erratum: Department of Error (Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials (2013) 382(9908) (1879–1888), (S0140673613617821), (10.1016/S0140-6736(13)61782-1));Safety and effi cacy of drug-eluting stents in women: A patient-level pooled analysis of randomised trials

The Lancet

Volumn 382, Issue 9908, 2013, Pages 1879-1888

  Stefanini, Giulio G ^a   Baber, Usman ^b   Windecker, Stephan ^a   Morice, Marie Claude ^v   Sartori, Samantha ^b   Leon, Martin B ^c   Stone, Gregg W ^c   Serruys, Patrick W ^q   Wijns, William ^d   Weisz, Giora ^c   Camenzind, Edoardo ^e   Steg, Philippe G ^g   Smits, Pieter C ^h   Kandzari, David ^j   Von Birgelen, Clemens ⁱ   Galatius, Soren ^k   Jeger, Raban V ^f   Kimura, Takeshi ^l   Mikhail, Ghada W ^m   Itchhaporia, Dipti ^r   Mehta, Laxmi ^t   Ortega, Rebecca ^s   Kim, Hyo Soo ⁿ   Valgimigli, Marco ^o   Kastrati, Adnan ^p   Chieffo, Alaide ^u   Mehran, Roxana ^b   more..

^a UNIVERSITY OF BERN   (Switzerland)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d CARDIOVASCULAR CENTER   (Belgium)

^e UNIVERSITY OF GENEVA   (Switzerland)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h Maasstad Hospital Rotterdam   (Netherlands)

ⁱ Thoraxcentrum Medisch Spectrum Twente   (Netherlands)

^j PIEDMONT HEART INSTITUTE   (United States)

^k GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^l KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^m IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

ⁿ Seoul National University   (South Korea)

^o UNIVERSITY OF FERRARA   (Italy)

^p TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^q ERASMUS MEDICAL CENTER   (Netherlands)

^r HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^s Society for Cardiovascular Angiography and Interventions   (United States)

^t THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^u SAN RAFFAELE HOSPITAL   (Italy)

^v Institut Cardiovasculaire   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYPHER AND CORDIS; ENDEAVOR; EVEROLIMUS; PACLITAXEL; PROMUS; RAPAMYCIN; RESOLUTE; TAXUS'; UMIROLIMUS; UNCLASSIFIED DRUG; YUKON; ZOTAROLIMUS;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DEATH; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FAMILY HISTORY; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INTENTION TO TREAT ANALYSIS; META ANALYSIS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; EQUIPMENT; FEMALE; HEART INFARCTION; METHODOLOGY; MORTALITY; RESTENOSIS; SEX DIFFERENCE; THROMBOSIS; TREATMENT OUTCOME; CORONARY RESTENOSIS; DEVICES; MYOCARDIAL INFARCTION; PROCEDURES;

CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX FACTORS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84889264879     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62625-2     Document Type: Erratum

References (48)

1. Stefanini GG, Holmes DR, Jr. Drug-eluting coronary-artery stents. N Engl J Med 2013; 368: 254-65.
2. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370: 937-48.
3. Baber U, Mehran R, Sharma SK, et al. Impact of the everolimuseluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol 2011; 58: 1569-77.
4. Stefanini GG, Kalesan B, Serruys PW, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011; 378: 1940-48.
5. Bangalore S, Kumar S, Fusaro M, et al. Short-and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117762 patient-years of follow-up from randomized trials. Circulation 2012; 125: 2873-91.
6. Go AS, Mozaff arian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013; 127: e6-e245.
7. US Food and Drug Administration. Draft guidance for industry and Food and Drug Administration staff : evaluation of sex diff erences in medical device clinical studies. http://www.fda.gov/MedicalDevices/ DeviceRegulationandGuidance/GuidanceDocuments/ucm283453. htm (accessed June 18, 2013).
8. SCAI Women in Innovations and the American College of Cardiology Gender Data Forum II: DES, revascularization, and complex PCI. http://www.scai.org/WIN/ Events/detail.aspx?cid=fa83feab-13d4-45eb-940a-def1a8f2b508 (accessed June 18, 2013).
9. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-80.
10. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-23.
11. Schofer J, Schluter M, Gershlick AH, et al, for the E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362: 1093-99.
12. Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004; 43: 1110-15.
13. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six-and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107: 38-42.
14. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the eff ectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108: 788-94.
15. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-31.
16. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymerbased paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005; 294: 1215-23.
17. Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005; 353: 653-62.
18. Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006; 114: 798-806.
19. Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006; 48: 2440-47.
20. Leon MB, Mauri L, Popma JJ, et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 2010; 55: 543-54.
21. Serruys PW, Ruygrok P, Neuzner J, et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. Eurointervention 2006; 2: 286-94.
22. Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008; 299: 1903-13.
23. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362: 1663-74.
24. Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, et al. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med 2010; 363: 2310-19.
25. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010; 375: 201-09.
26. Smits PC, Hofma S, Togni M, et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet 2013; 381: 651-60.
27. Park KW, Chae IH, Lim DS, et al. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Effi cacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial. J Am Coll Cardiol 2011; 58: 1844-54.
28. Kimura T, Morimoto T, Natsuaki M, et al. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial (RESET). Circulation 2012; 126: 1225-36.
29. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363: 136-46.
30. von Birgelen C, Basalus MW, Tandjung K, et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol 2012; 59: 1350-61.
31. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008; 372: 1163-73.
32. Byrne RA, Kastrati A, Kufner S, et al. Randomized, non-inferiority trial of three limus agent-eluting stents with diff erent polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Effi cacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J 2009; 30: 2441-49.
33. Valgimigli M, Campo G, Monti M, et al. Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012; 125: 2015-26.
34. Camenzind E, Wijns W, Mauri L, et al, for the PROTECT Steering Committee and Investigators. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet 2012; 380: 1396-405.
35. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized defi nitions. Circulation 2007; 115: 2344-51.
36. Therneau TM, Grambsch PM, Pankratz VS. Penalized survival models and frailty. J Comput Graph Stat 2003; 12: 156-75.
37. Glidden DV, Vittingho E. Modelling clustered survival data from multicenter clinical trials. Statist Med 2004; 23: 369-88.
38. Lansky AJ, Costa RA, Mooney M, et al. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. J Am Coll Cardiol 2005; 45: 1180-85.
39. Solinas E, Nikolsky E, Lansky AJ, et al. Gender-specifi c outcomes after sirolimus-eluting stent implantation. J Am Coll Cardiol 2007; 50: 2111-16.
40. Mikhail GW, Gerber RT, Cox DA, et al. Infl uence of sex on long-term outcomes after percutaneous coronary intervention with the paclitaxel-eluting coronary stent: results of the "TAXUS Woman" analysis. JACC Cardiovasc Interv 2010; 3: 1250-59.
41. Stefanini GG, Kalesan B, Pilgrim T, et al. Impact of sex on clinical and angiographic outcomes among patients undergoing revascularization with drug-eluting stents. JACC Cardiovasc Interv 2012; 5: 301-10.
42. Anderson ML, Peterson ED, Brennan JM, et al. Short-and long-term outcomes of coronary stenting in women versus men: results from the National Cardiovascular Data Registry Centers for Medicare & Medicaid services cohort. Circulation 2012; 126: 2190-99.
43. Kramer DB, Mallis E, Zuckerman BD, Zimmerman BA, Maisel WH. Premarket clinical evaluation of novel cardiovascular devices: quality analysis of premarket clinical studies submitted to the Food and Drug Administration 2000-2007. Am J Ther 2010; 17: 2-7.
44. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007; 369: 667-78.
45. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012; 379: 1393-402.
46. Stone GW, Kedhi E, Kereiakes DJ, et al. Diff erential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation 2011; 124: 893-900.
47. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012; 367: 2375-84.
48. Naggara O, Raymond J, Guilbert F, Altman DG. The problem of subgroup analyses: an example from a trial on ruptured intracranial aneurysms. AJNR Am J Neuroradiol 2011; 32: 633-66.